These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 7524579)

  • 1. Intensive chemotherapy with high-dose epirubicin every 2 weeks and prophylactic administration of filgrastim in advanced breast cancer.
    Fountzilas G; Skarlos D; Giannakakis T; Athanasiades A; Bafaloukos D; Kalogera-Fountzila A; Bamia C; Pavlidis N; Kosmidis P
    Eur J Cancer; 1994; 30A(7):965-9. PubMed ID: 7524579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose epirubicin and r-met-hu G-CSF (filgrastim) in the treatment of patients with advanced breast cancer: A Hellenic Cooperative Oncology Group study.
    Fountzilas G; Skarlos D; Katsohis C; Pavlidis N; Giannakakis T; Bafaloukos D; Fahantidis E; Klouvas G; Beer M; Kosmidis P
    Med Pediatr Oncol; 1995 Jan; 24(1):23-8. PubMed ID: 7526143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study.
    Therasse P; Mauriac L; Welnicka-Jaskiewicz M; Bruning P; Cufer T; Bonnefoi H; Tomiak E; Pritchard KI; Hamilton A; Piccart MJ;
    J Clin Oncol; 2003 Mar; 21(5):843-50. PubMed ID: 12610183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An EORTC pilot study of filgrastim (recombinant human granulocyte colony stimulating factor) as support to a high dose-intensive epiadriamycin-cyclophosphamide regimen in chemotherapy-naive patients with locally advanced or metastatic breast cancer.
    Piccart MJ; Bruning P; Wildiers J; Awada A; Schornagel JH; Thomas J; Tomiak E; Bartholomeus S; Witteveen PO; Paridaens R
    Ann Oncol; 1995 Sep; 6(7):673-7. PubMed ID: 8664188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicycle high-dose chemotherapy and filgrastim-mobilized peripheral-blood progenitor cells in women with high-risk stage II or III breast cancer: five-year follow-up.
    Basser RL; To LB; Collins JP; Begley CG; Keefe D; Cebon J; Bashford J; Durrant S; Szer J; Kotasek D; Juttner CA; Russell I; Maher DW; Olver I; Sheridan WP; Fox RM; Green MD
    J Clin Oncol; 1999 Jan; 17(1):82-92. PubMed ID: 10458221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II study of a dose-density regimen with fluorouracil, epirubicin, and cyclophosphamide on days 1 and 4 every 14 days with filgrastim support followed by weekly paclitaxel in women with primary breast cancer.
    Pietri E; Andreis D; Fabbri F; Menna C; Schirone A; Kopf B; Rocca A; Amadori D; De Giorgi U
    Oncologist; 2015 Mar; 20(3):239-40. PubMed ID: 25637379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial.
    Cameron D; Morden JP; Canney P; Velikova G; Coleman R; Bartlett J; Agrawal R; Banerji J; Bertelli G; Bloomfield D; Brunt AM; Earl H; Ellis P; Gaunt C; Gillman A; Hearfield N; Laing R; Murray N; Couper N; Stein RC; Verrill M; Wardley A; Barrett-Lee P; Bliss JM;
    Lancet Oncol; 2017 Jul; 18(7):929-945. PubMed ID: 28600210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Docetaxel and epirubicin supported by granulocyte colony-stimulating factor first-line in advanced breast cancer.
    Polyzos A; Tsavaris N; Kosmas C; Gogas H; Vadiaka M; Markopoulos C; Giannopoulos A; Kalahanis N; Stamatiadis D; Kouraklis G; Karatzas G; Liapis C; Syrigos K
    Anticancer Res; 2003; 23(3C):2917-23. PubMed ID: 12926135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of schedule on acute toxicity and dose-intensity of high-dose chemotherapy with epirubicin and cyclophosphamide plus colony stimulating factors in advanced breast cancer.
    De Placido S; Lauria R; Carlomagno C; Perrone F; De Laurentiis M; Gallo C; Martignetti A; Bellelli T; Limite G; Petrella G; Bianco AR
    Int J Oncol; 1999 Aug; 15(2):339-46. PubMed ID: 10402245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Filgrastim and lack of support of intensive adjuvant chemotherapy for high-risk breast cancer patients.
    Baldini E; Tibaldi C; Lencioni M; Giannessi P; Evangelista G; Roncella M; Spinelli C; Meucci C; da Prato M; Conte P
    Am J Clin Oncol; 1997 Apr; 20(2):169-72. PubMed ID: 9124194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II study of high-dose epirubicin (EPI) plus cyclophosphamide (CPA) with G-CSF for breast cancer patients with visceral metastases or hormone-independent tumors: a trial of the Japan Clinical Oncology Group.
    Takashima S; Saeki T; Adachi I; Watanabe T; Sasaki Y; Murai H; Tabei T; Ogita M; Sano M; Kanda K; Shimoyama M
    Jpn J Clin Oncol; 1997 Oct; 27(5):325-30. PubMed ID: 9390210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support.
    Morgan RJ; Doroshow JH; Venkataraman K; Chang K; Raschko J; Somlo G; Leong L; Tetef M; Shibata S; Hamasaki V; Margolin K; Forman S; Akman S; Coluzzi P; Ahn C; Weiss L; Gadgil U; Harrison J
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2337-45. PubMed ID: 9815632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study of paclitaxel and epirubicin, without and with filgrastim, for the treatment of platinum-resistant advanced ovarian cancer.
    Lauria R; Ferrari E; Tramontana S; Morabito A; Perrone F; Maffeo A; Fiorentino R; Casella G; Iodice F; Ricchi P; Carlomagno C; Varriale E; De Placido G; De Placido S; Bianco AR; Pignata S
    Oncology; 1999; 56(4):267-73. PubMed ID: 10343189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid hematopoietic recovery after multicycle high-dose chemotherapy: enhancement of filgrastim-induced progenitor-cell mobilization by recombinant human stem-cell factor.
    Basser RL; To LB; Begley CG; Maher D; Juttner C; Cebon J; Mansfield R; Olver I; Duggan G; Szer J; Collins J; Schwartz B; Marty J; Menchaca D; Sheridan WP; Fox RM; Green MD
    J Clin Oncol; 1998 May; 16(5):1899-908. PubMed ID: 9586908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial of high-dose mitoxantrone plus cyclophosphamide and filgrastim in patients with advanced breast carcinoma.
    Sparano JA; Robert N; Silverman P; Lazarus H; Malik U; Venkatraj U; Sarta C
    J Clin Oncol; 1996 Sep; 14(9):2576-83. PubMed ID: 8823338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biweekly docetaxel-irinotecan with filgrastim support in pretreated breast and non-small-cell lung cancer patients. A phase I study.
    Frasci G; Comella P; Thomas R; Di Bonito M; Lapenta L; Capasso I; Botti G; Vallone P; De Rosa V; D'Aiuto G; Comella G
    Cancer Chemother Pharmacol; 2004 Jan; 53(1):25-32. PubMed ID: 14513281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A dose-finding study of epirubicin in combination with paclitaxel in the treatment of advanced breast cancer.
    Conte PF; Michelotti A; Baldini E; Salvadori B; Gennari A; Da Prato M; Tibaldi C; Salzano E; Gentile A
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):28-31. PubMed ID: 8893896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inflammatory breast cancer outcome with epirubicin-based induction and maintenance chemotherapy: ten-year results from the French Adjuvant Study Group GETIS 02 Trial.
    Veyret C; Levy C; Chollet P; Merrouche Y; Roche H; Kerbrat P; Fumoleau P; Fargeot P; Clavere P; Chevallier B
    Cancer; 2006 Dec; 107(11):2535-44. PubMed ID: 17054108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study.
    Miller AA; Hargis JB; Lilenbaum RC; Fields SZ; Rosner GL; Schilsky RL
    J Clin Oncol; 1994 Dec; 12(12):2743-50. PubMed ID: 7527456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer patients.
    Shapiro CL; Ayash L; Webb IJ; Gelman R; Keating J; Williams L; Demetri G; Clark P; Elias A; Duggan D; Hayes D; Hurd D; Henderson IC
    J Clin Oncol; 1997 Feb; 15(2):674-83. PubMed ID: 9053493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.